TRACELLS is a pioneering health diagnostics company developing a cutting-edge, cost-effective stool test platform for diagnosing Inflammatory Bowel Disease (IBD) and related gastrointestinal (GI) disorders. The company’s proprietary platform uses transcriptomics—comprehensive RNA AI driven analysis—to examine RNA in stool samples, providing high-accuracy insights into disease severity, location, and unique molecular signatures of specific bowel disorders to drive personalized treatment. TRACELLS' initial focus is on IBD, with plans to expand into additional GI conditions.